Skip to main content

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma
Learning Library

New & Trending

EZH2
Rapid Refresh
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
Oncology Learning Network APP Institute
Oluwatobi Odetola, MD,
Conference Coverage
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
From Oncology
Narendranath Epperla, MD, MS
Conference Coverage
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
From Oncology

Clinical Pearls

APP Perspectives

Lorinda Coombs
APP Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
Oncology Learning Network APP Institute

Conference Coverage

Oluwatobi Odetola, MD,
Conference Coverage
12/12/2023
Oluwatobi Odetola, MD
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
12/11/2023
Narendranath Epperla, MD, MS
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Conference Coverage
05/19/2026
Kirra Fedyszyn
Study findings show cancer patients undergoing radiation therapy may interpret “stress” and “distress” differently—or use the terms interchangeably—raising important considerations for symptom assessment and supportive oncology care.
Study findings show cancer patients undergoing radiation therapy may interpret “stress” and “distress” differently—or use the terms interchangeably—raising important considerations for symptom assessment and supportive oncology care.
Study findings show cancer...
05/19/2026
Oncology Learning Network APP Institute
Conference Coverage
05/19/2026
Kirra Fedyszyn
Advanced practice provider (APP)-led telehealth education increased patient engagement in cancer symptom self-management, with patients making significantly more proactive symptom support calls during treatment. However, the intervention did...
Advanced practice provider (APP)-led telehealth education increased patient engagement in cancer symptom self-management, with patients making significantly more proactive symptom support calls during treatment. However, the intervention did...
Advanced practice provider...
05/19/2026
Oncology Learning Network APP Institute
Conference Coverage
05/18/2026
Kirra Fedyszyn
A patient-navigation platform designed to address social determinants of health may improve workflow efficiency and social support delivery in community oncology practices, according to preliminary implementation data.
A patient-navigation platform designed to address social determinants of health may improve workflow efficiency and social support delivery in community oncology practices, according to preliminary implementation data.
A patient-navigation platform...
05/18/2026
Oncology Learning Network APP Institute
Conference Coverage
05/18/2026
Kirra Fedyszyn
Community health worker-led education and human papillomavirus (HPV) self-sampling may improve cervical cancer screening access among women experiencing homelessness, a population with disproportionately high cervical cancer burden.
Community health worker-led education and human papillomavirus (HPV) self-sampling may improve cervical cancer screening access among women experiencing homelessness, a population with disproportionately high cervical cancer burden.
Community health worker-led...
05/18/2026
Oncology Learning Network APP Institute
Conference Coverage
05/18/2026
Kirra Fedyszyn
Daily fluctuations in cognitive symptoms may predict lower quality of life and greater social dysfunction in women living with metastatic breast cancer, according to prospective real-world assessment data.
Daily fluctuations in cognitive symptoms may predict lower quality of life and greater social dysfunction in women living with metastatic breast cancer, according to prospective real-world assessment data.
Daily fluctuations in cognitive...
05/18/2026
Oncology Learning Network APP Institute
Conference Coverage
05/18/2026
Kirra Fedyszyn
A rural cancer program successfully implemented local administration of bispecific T-cell engager (BiTE) therapy, reducing travel burden while safely delivering treatment for patients with hematologic malignancies.
A rural cancer program successfully implemented local administration of bispecific T-cell engager (BiTE) therapy, reducing travel burden while safely delivering treatment for patients with hematologic malignancies.
A rural cancer program...
05/18/2026
Oncology Learning Network APP Institute
Conference Coverage
05/18/2026
Kirra Fedyszyn
A multimodal education program achieved high competency rates among inpatient and outpatient nurses in recognizing and managing toxicities associated with cellular immunotherapies, including cytokine release syndrome (CRS) and immune effector...
A multimodal education program achieved high competency rates among inpatient and outpatient nurses in recognizing and managing toxicities associated with cellular immunotherapies, including cytokine release syndrome (CRS) and immune effector...
A multimodal education program...
05/18/2026
Oncology Learning Network APP Institute
Conference Coverage
05/18/2026
Kirra Fedyszyn
Expert guidance highlights the critical role oncology nurses and advanced practice providers play in early recognition and management of trastuzumab deruxtecan-related interstitial lung disease in routine cancer care.
Expert guidance highlights the critical role oncology nurses and advanced practice providers play in early recognition and management of trastuzumab deruxtecan-related interstitial lung disease in routine cancer care.
Expert guidance highlights the...
05/18/2026
Oncology Learning Network APP Institute
Conference Coverage
05/15/2026
Kirra Fedyszyn
Real-world data show rapid growth in utilization of molecular residual disease (MRD) testing in the United States, across multiple cancer types, with increasing use beyond early-stage settings into advanced and metastatic disease.
Real-world data show rapid growth in utilization of molecular residual disease (MRD) testing in the United States, across multiple cancer types, with increasing use beyond early-stage settings into advanced and metastatic disease.
Real-world data show rapid...
05/15/2026
Oncology Learning Network APP Institute
Conference Coverage
05/15/2026
Kirra Fedyszyn
Emerging evidence links gut microbiome profiles to fatigue and other psychoneurological symptoms in melanoma patients receiving immune checkpoint inhibitors, suggesting a potential biological pathway for symptom burden during treatment.
Emerging evidence links gut microbiome profiles to fatigue and other psychoneurological symptoms in melanoma patients receiving immune checkpoint inhibitors, suggesting a potential biological pathway for symptom burden during treatment.
Emerging evidence links gut...
05/15/2026
Oncology Learning Network APP Institute